Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores

Loading news article.

Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores | WAPE

Veracyte Says Phase III STAMPEDE Analysis Shows Decipher Prostate Test Predicts Benefit Of Adding Abiraterone To ADT In Very High-Risk Nonmetastatic Prostate Cancer, With 10-11% Absolute Benefit At Five Years For High-Scoring Patients Versus 2% For Lower Scores

Article summary

Related companies

Comments —